ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(14 sites)

Canada

Novartis Investigative Site, Calgary, Alberta

Novartis Investigative Site, Edmonton, Alberta

Novartis Investigative Site, Burnaby, British Columbia

Novartis Investigative Site, Vancouver, British Columbia

Novartis Investigative Site, St. John's, Newfoundland and Labrador

Novartis Investigative Site, Halifax, Nova Scotia

Novartis Investigative Site, Ottawa, Ontario

Novartis Investigative Site, Montreal, Quebec

Novartis Investigative Site, Québec, Quebec

Novartis Investigative Site, Sherbrooke, Quebec